Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer.

Rouach, Vanessa; Goldshtein, Inbal; Wolf, Ido; Catane, Raphael; Chodick, Gabriel; Iton, Amit; Stern, Naftali; Cohen, Daniel

Rouach, Vanessa; Goldshtein, Inbal; Wolf, Ido; Catane, Raphael; Chodick, Gabriel; Iton, Amit; Stern, Naftali; Cohen, Daniel.

Afiliação

Rouach V; Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Weizmann 6', Tel Aviv, Israel.
Goldshtein I; School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Tel Aviv University, Israel.
Wolf I; Epidemiology & Database Research, Maccabi Healthcare Services, Israel.
Catane R; Oncology Division, Tel Aviv Sourasky Medical Center, Israel.
Chodick G; Oncology Division, Sheba Medical Center, Israel.
Iton A; Epidemiology & Database Research, Maccabi Healthcare Services, Israel.
Stern N; School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Tel Aviv University, Israel.
Cohen D; Sackler School of Medicine, Tel Aviv University, Israel.

J Bone Oncol ; 12: 91-95, 2018 Sep.

Article em En | MEDLINE | ID: mdl-30148062

Palavras-chave

Alendronate; Bisphosphonates; Bone metastases; Breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google